RE:RE:Here are some recent ProMetic Life Sciences analyst reportsMany 12 month targets are now at 1.00 or less (analysts are great, they just cut their targets in half without even saying oops sorry!), with roughly 600 M issued shares (excl Thomvest), with let's say a global average purchase price of 1.50$, that's roughly 300 M$ aggregate investor losses out there... Just back of the napkin calc. Hope that BOD and management are at least a bit nervous ahead of the AGM. Not even sure they are... GLTA